Castleview Partners’s Biogen BIIB Stock Holding History

Castleview Partners’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-28	Closed	-$6.49K	–	582
2024 Q2	$6.49K	Buy	28 +5	+22%	+$1.09K	﹤0.01%	592
2024 Q1	$4.96K	Hold	23	–	–	﹤0.01%	635
2023 Q4	$5.95K	Hold	23	–	–	﹤0.01%	562
2023 Q3	$5.91K	Hold	23	–	–	0.01%	468
2023 Q2	$6.55K	Hold	23	–	–	0.01%	478
2023 Q1	$6.39K	Hold	23	–	–	0.01%	472
2022 Q4	$6.37K	Hold	23	–	–	0.01%	423
2022 Q3	$6K	Sell	23 -2	-8%	-$425	0.01%	430
2022 Q2	$15.2K	Buy	25 +2	+9%	+$409	0.01%	414
2022 Q1	$4K	Buy	+23	New	+$5K	﹤0.01%	584
2021 Q2	$8K	Buy	+23	New	+$6.97K	﹤0.01%	733

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Castleview Partners's BIIB Position: Q3 2024 in Review

Castleview Partners sold out of Biogen (BIIB) in Q3 2024, closing a stake of 28 shares — an estimated $6.49K sold.

Castleview Partners first reported a position in BIIB in Q2 2021 and held it in 11 quarters. The position peaked at $15.2K in Q2 2022. 917 funds tracked by Wall St. Rank hold BIIB as of Q3 2024.

Castleview Partners reported no remaining Biogen position as of Q3 2024 after selling out during the quarter.
Castleview Partners sold 28 Biogen shares in Q3 2024, an estimated $6.49K.
Castleview Partners first reported a position in Biogen in Q2 2021 and held it in 11 quarters.
Castleview Partners's Biogen position peaked at $15.2K in Q2 2022.
917 funds tracked by Wall St. Rank held Biogen as of Q3 2024.

Based on Castleview Partners's 13F filing for Q3 2024, filed 9 Oct 2024.